Clinicopathological and prognostic significance of epidermal growth factor receptor overexpression in patients with esophageal adenocarcinoma: a meta-analysis
- PMID: 24961755
- DOI: 10.1111/dote.12248
Clinicopathological and prognostic significance of epidermal growth factor receptor overexpression in patients with esophageal adenocarcinoma: a meta-analysis
Abstract
The prognostic significance of epidermal growth factor receptor (EGFR) overexpression in patients with esophageal adenocarcinoma (EAC) remains controversial. Eligible studies that investigated the association between survival in EAC and the expression status of EGFR were identified by an electronic search of PubMed, EMBASE, and ISI Web of Science. A meta-analysis was performed to clarify the impact of EGFR overexpression on clinicopathological parameters or overall survival (OS) in EAC. A total of seven studies including 1028 patients were subjected to the final analysis. The overall results suggested that overexpression of EGFR was significantly correlated with not only the depth of invasion, lymph node status, and tumors stage of EAC, with a pooled odds ratio of 2.99 (95% confidence interval [CI]: 1.07-8.35; Z = 2.09; P = 0.037), 3.05 (95% CI: 1.77-5.27; Z = 4.00; P < 0.001), and 5.37 (95% CI: 2.49-11.57; Z = 4.29; P < 0.001), respectively, but also the poorer OS with a pooled hazard ratio of 2.20 (95% CI: 1.47-3.31; Z = 3.79; P < 0.001). Overexpression of EGFR correlates with not only the clinicopathological features, but also the worse OS, and it might be useful as a predictive biomarker in clinical practice, yet the clinicopathological and prognostic role of EGFR in EAC still needs further confirmation by well-designed prospective studies.
Keywords: epidermal growth factor receptor; esophageal adenocarcinoma; meta-analysis; prognosis.
© 2014 International Society for Diseases of the Esophagus.
Similar articles
-
Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.Hum Pathol. 2013 May;44(5):829-36. doi: 10.1016/j.humpath.2012.08.005. Epub 2012 Nov 14. Hum Pathol. 2013. PMID: 23158210
-
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.Cancer. 2007 Feb 15;109(4):658-67. doi: 10.1002/cncr.22445. Cancer. 2007. PMID: 17211865
-
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.PLoS One. 2016 Feb 4;11(2):e0148101. doi: 10.1371/journal.pone.0148101. eCollection 2016. PLoS One. 2016. PMID: 26844548 Free PMC article.
-
Role of human epidermal growth factor receptor 2 as a prognostic factor for survival in esophageal carcinoma: evidence from 2872 subjects.Minerva Med. 2016 Oct;107(5):328-41. Epub 2016 Jun 16. Minerva Med. 2016. PMID: 27309036 Review.
-
C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis.Panminerva Med. 2017 Mar;59(1):97-106. doi: 10.23736/S0031-0808.16.03228-6. Epub 2016 Sep 16. Panminerva Med. 2017. PMID: 27636117 Review.
Cited by
-
Prognostic significance of epidermal growth factor receptor expression in glioma patients.Onco Targets Ther. 2018 Feb 7;11:731-742. doi: 10.2147/OTT.S155160. eCollection 2018. Onco Targets Ther. 2018. PMID: 29445288 Free PMC article.
-
Lack of Association between Epidermal Growth Factor or Its Receptor and Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma: A Case-Control Study.Dis Markers. 2022 Aug 31;2022:8790748. doi: 10.1155/2022/8790748. eCollection 2022. Dis Markers. 2022. PMID: 36092955 Free PMC article.
-
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed.Cancer Chemother Pharmacol. 2021 Mar;87(3):361-377. doi: 10.1007/s00280-020-04187-w. Epub 2020 Nov 9. Cancer Chemother Pharmacol. 2021. PMID: 33169187 Free PMC article.
-
Current status and perspectives of esophageal cancer: a comprehensive review.Cancer Commun (Lond). 2025 Mar;45(3):281-331. doi: 10.1002/cac2.12645. Epub 2024 Dec 26. Cancer Commun (Lond). 2025. PMID: 39723635 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous